The drugmaker posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.
Tag Archive for: Bristol-Myers Squibb
Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.
The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Here are some strategies company are employing to manage the drop in revenue.
After winning approval earlier this month in follicular lymphoma, Bristol Myers Squibb’s Breyanzi got the FDA nod for another indication on Thursday: relapsed or refractory mantle cell lymphoma (MCL). Find out what other FDA approvals have recently gone through.
During the first quarter of the 2024 earnings season, large drugmakers Bayer and Bristol Myers Squibb announced thousands of layoffs in two of the largest workforce reductions so far this year. Coming off years of upheaval in the biotech and pharma sectors, will this be a temporary bump in the road or the beginning of a significant wave of Big Pharma layoffs?
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.
Carlos Dortrait, senior vice president & general manager of U.S. Immunology & Neuroscience at Bristol Myers Squibb, explains the importance of empowering patients and giving them the confidence to speak with doctors so they can seek the treatment they need, in this case for treating plaque psoriasis. Actress, writer, and producer Mindy Kaling recently joined actor Ted Danson in the BMS “SO, Have You Found It?” campaign (with their video slated to be released soon), which aims to strengthen the voices of U.S. patients living with the condition. Danson has been living with plaque psoriasis for many years and Kaling, who does not have psoriasis, has the role of patient empowerment through self advocacy.
Following back-to-back approvals in lymphocytic leukemia, Bristol Myers Squibb’s CAR-T therapy Breyanzi on Wednesday won the FDA’s green light for relapsed or refractory follicular lymphoma.
According to Repertoire, the deal will use its Decode discovery platform to find the vaccine candidates. Decode is a T cell receptor-epitope platform using proprietary lipid nanoparticle delivery technology. The biotech said that the vaccines will aim to treat the underlying causes by “resetting” the immune system.
Yesterday a U.S. judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government’s Medicare health insurance program or pay heavy penalties.